Iam CBFB-MYH11 Kit

Background

CBFB-MYH11, also known as PEBP2B-MYH11, inv(16), t(16;16) is a recurrent genetic abnormality especially in adult Acute Myeloid Leukemia (10% of all de novo AML). This translocation is also one of the most frequently balanced chromosomal translocations found in patients with therapy-related AML (t-AML). Although this genetic alteration is associated with a good prognosis, 30%-40% of these patients experience relapse and its rapid molecular identification is considered crucial for patients’ management and therapeutic decisions.

Why to choose it

Comprehensive molecular identification of common (Type A) and rare (Type D and E) isoforms of CBFB-MYH11 fusion in a single rapid step.

Benefits

Ultra Rapid

Identification of positive samples in less than 20 minutes, starting form extracted RNA

Easy to set up

Retrotrascription, amplification and data elaboration happen on board the LIAISON IAM in a close tube, one-step format

Highly reliable

Internal endogenous control and quality controls are included to allow validation of results

Highly Specific 

No false positive results and absence of primer dimers

The Analytical Specificity has been established on negative cell line RNA extracted by both the Qiagen RNeasy kit and modified Trizol

Clinically Validated

The analysis has been performed on clinical samples using RNA extracted by Qiagen RNeasy kit or modified TRIzol protocol and demonstrates a complete concordance with the reference method.

TOTAL REPLICATES                67                             100%

Robust

Superior robustness to inhibitors, RNA degradation and suboptimal target quantities.

The intrinsic robustness of the enzyme employed in Q-LAMP results in a enhanced robustness versus the classical inhibitor factors of PCR.

Superiority vs. PCR

Q-LAMP is a very rapid, easy, accurate, convenient and robust method for detection of BCR-ABL translocations.

Can be implemented even in not specialized laboratories for a timely Philadelphia Positive Leukemias diagnosis and as a screening for exclusion of Philadelphia Positive conditions.

For use on

LIAISON IAM Brochure

Ordering Info